Should Vytoringate Cost Fred Hassan His Bonus?

Schering-Plough CEO Fred Hassan looked like quite the turnaround artist as he nursed the company back to health after it had been battered by generic competition for Claritin and regulatory problems. Lately, though, things have taken a gloomy turn for Schering-Plough as cholesterol drugs Vytorin and Zetia — and the company’s stock price — have [...]